Biocon gets FDA nod for cancer drugs lenalidomide and dasatinib

Biocon Pharma also received tentative approval of its ANDA for rivaroxaban Tablets USP, in 2.5 mg, 10 mg, 15 mg and 20 mg strengths. Shares of Biocon Ltd ended at ₹314.80, up by ₹9.90, or 3.25%, on the BSE.